Revenue ($USD) : $6,239,280,870 Revenue (foreign currencies) : JP¥820,209,000,000 R&D spend : $468,458,203.00 Employees : 30,207 Fiscal year end : 03/31/23 CEO : Shinjiro Sato, president and CEO
Terumo Aortic earlier this year announced the first implant of its custom-made thoracoabdominal hybrid device, Thoracoflo, in North America. Thoracoflo uses a combination of Terumo Aortic’s Gelweave woven polyester grafts and ring-stent technology to address a patient’s specific anatomy. Terumo’s wide range of products include interventional cardiology, blood transfusion and cell therapy. –CN and DK